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doi:10.1016/j.ejvs.2008.10.012Abstract Objective: The aim of the study was to evaluate the use of a decellularised scaffold
and its re-endothelialisation in vitro in order to create human vascular substitutes containing
venous valves. This research is clinically relevant particularly with regard to the development
of venous (valve containing) transplants to replace a diseased femoral vein valve and/or ob-
structed veins. This technique may enable causal treatment of venous reflux and obstructions.
Materials and methods: Valve-bearing segments of human allogeneic great saphenous veins
(GSVs) were decellularised using sodium deoxycholic acid (SD) and treated with DNase I.
Human venous endothelial cells (ECs) were enzymatically harvested from the GSV, expanded
up to the 3rd passage using FCS (nZ 20) or human AB serum (hABS; nZ 8) supplemented
media before used for re-seeding. In special bioreactors, 3D re-seeding of 28 decellularised
GSV was performed with constant perfusion (A; nZ 8), bidirectional perfusion (B; nZ 8), bidi-
rectional perfusion/reduced flow (C; nZ 2), static conditions (D; nZ 2), and bidirectional
perfusion/reduced flow using hABS (E; nZ 8) instead of FCS. Decellularised GSV, scaled-up
EC and 3D-seeded tissue-engineered valve containing neo-veins underwent immunohistochem-
ical and PCR characterisation.
Results: Intact collagen and elastin networks as well as complete acellularity were shown after
GSV decellularisation. In EC culture, supplementation with hABS led to a significantly higher
expression of vWF compared to FCS (pZ 0.025). Additional EC markers such as CD 31, FLK-1
and VE-Cadherin were not altered. EC re-seeding using hABS supplemented medium (E) led to
a confluent monolayer of cells that were immunohistochemically positive for FLK-1, CD 31,
vWF and VE-Cadherin and by means of PCR after RNA preparation in 7 of 8 cases but was unsuc-
cessful if FCS was used (AeD). In AeD cells presented as conglomerates positive for CD 31 and
VE-Cadherin, suggesting sufficient intercellular contact but not cellematrix contact.en, MD, Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical
1, D-30625 Hannover, Germany. Tel.: þ49 5115326589; fax: þ49 5115325404.
H-Hannover.de (O.E. Teebken).
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Venous Tissue Engineering 93Table 1a Results of internal val
Author(s) Main implan
site
Kistner22 FV
Ferris and Kistner23 FV
Raju24 FV
Eriksson and
Almgren (1986)25
FV
Hoshino et al.26 FV
Cheatle and Perrin27 FV
Masuda and Kistner28 FV
Raju et al.29 FV
Lurie et al.30 FV
Perrin31
Perrin et al.32 FV
Perrin33 FV
Raju et al.34 FV
Tripathi and
Ktenidis35
FV
(veno) Determined by venography.
PVI, primary venous insufficiency (d
femoral vein.
a Determined by venogram or Dop
b Includes skin changes, edema, p
c Determined by plethysmography
when compared with preoperative v
d Determined by Doppler ultrasono
e Immediately after surgery.
f Twelve months after surgery.Conclusions: Treatment with SD and DNase enables complete decellularisation of human valve
containing veins whereas 3D matrix components such as collagen and elastin remain preserved.
The lumen of the scaffold including the valves can be successfully re-seeded with a human EC
monolayer in a 3D bioreactor. There is substantial evidence that hABS and not FCS is essential
for the completion of cellematrix contacts in human veins.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Chronic deep vein incompetence is an economically
important and frequent disorder in Europe and North
America.1,2 Iliofemoral vein obstruction and venous reflux
in the leg are considered responsible for the symptoms of
chronic venous insufficiency such as swelling, pain,
venous claudication and skin changes.3,4 Apart from
external compression therapy, superficial vein surgery and
endovascular recanalisation a variety of surgical attempts
such as vein valve repair, transfer, transposition or
transplantation of artificial vein valves have been
described to restore valve function (Tables 1a and 1b).5e7
We have shown in a lamb model previously that valved
venous conduits can be successfully generated from
a matrix decellularised with sodium deoxycholate (SD)
and DNase that was re-seeded with autologous cells.vuloplasty (modified from Ref.
tation Number
of limbs
Months’
follow-up
(mean)
N
15 36e84 (60) 0
32 12e156 (72)
15 3e40
19 84 (44) 1
7 2e28 7
52 3e54 4
32 48e256 (127)
81 12e144
49 36e108 (74)
75 24e96 (58) 5
33 24e96 (51) 2
85 12e96 (58) 6
141 1e42 9
25 1e12 (6) 2
etermined by the authors based
pler/duplex ultrasonography.
ain, and ulcer recurrence.
or ambulatory venous pressure me
alues).
graphy.Morphological appearance and valve function resembled
a native vein.4
The combination of SD and a DNAespecific endonuclease
cleavage to decellularise human venous tissue has not been
previously reported. Possible advantages to its use include
preservation of extracellular matrix important for strength
and cell attachment, and avoidance of problems associated
with aldehyde-fixed tissues (poor graft compliance and
aneurismal degeneration). Autologous cell seeding prior to
implantation reduces or eliminates immunologic response
and thrombogenicity, the most important cause of graft
obstruction of small calibre grafts and in the venous
circulation.
In this experimental study it was our aim to clarify, if
decellularisation and re-seeding protocols established in
a growing lamb model can be transferred into a human in
vitro model using tissue and cells obtained from patients21)
o. PVI No.
competenta
No. patenta Recurrence/
unchangedb
Hemodynamic
improvementc
/15 5/14 14/14 2/15
16/22 6/32 7/8
15/15d 0/15 10/15
4/5(veno)
9/19 13/19 5/19 12/19
/7 7/7 7/7 0
0/52 46/52e 48/52e 7/51 40/42e
23/27f 26/27f 24/25f
24/31 9/32
30/71 16/68
18/49
5/75 50/74 6/33 54/74
2/33 22/33 6/33 16/27
5/85 51/83 10/35 43/68
8/141 85/109
5/25 35/41 39/41 4/25
on a lack of venous thrombosis detected in the patients); FV,
asurements (improvement in hemodynamic tests postoperatively
Table 1b Results of valve transplantation, including autografts, xenografts and human allografts (modified from Ref. 21)
Author(s) Main implantation
site
Number
of limbs
Follow-up
(months)
(mean)
No. PVI No.
competenta
No. patenta Recurrence/
unchangedb
Hemodynamic
improvementc
Taheri et al.36 FV 6 12 0/6 4/4 4/4 5/5d 5/5
Raju24 FV 21 3e40 2/14 10/21 10/13
Taheri et al.37 POP 46 8e36 22/24 21/24 5/46 12/14
O’Donnell et al.38 POP 10 >24 0/10 10/10 0/10 1/10
Nash39 POP 25 12e18 0/25 20/25 25/25 2/25 21/25
Rai and Lerner40 POP 12 6e24 (16) 6/6 9/9 0/12(veno) 11/12
Bry et al.41 POP 15 15e132 (64) 0/15 14/14 3/14
Perrin31 FV 30 12e120 (58) 1/30 6/20 6/20 8/20
Sottiurai42 31 8e156 (74) 14/31 17/31
Garcia-Rinaldi
et al.43
FV, allograft pulmonary
artery, monocusp
36 >12 36/36 36/36 5/12
Proebstle et al.44 FV, bovine jugular
vein valve
5 18 0/6 0/5 2/5
Neglen and Raju45 FV, cryovalve 25 1e41 (11) 0/25 8/27 12/27
(veno) Two patients required skin graft to heal ulcer.
PVI, primary venous insufficiency (determined by the authors based on a lack of venous thrombosis detected in the patients); FV,
femoral vein; POP, popliteal vein.
a Determined by venogram or Doppler/duplex ultrasonography.
b Includes skin changes, edema, pain, and ulcer recurrence.
c Determined by plethysmography or ambulatory venous pressure measurements (improvement in hemodynamic tests postoperatively
when compared with preoperative values).
d Four of five received skin graft.
94 O.E. Teebken et al.suffering from cardiovascular diseases. In addition, the
effect of medium composition and flow parameters on EC
confluence after re-seeding should be elucidated with
respect to the development of a venous valve-bearing graft
having good in vitro properties indicating suitability for
implantation.
Materials and Methods
The study was conducted under protocols approved by the
local Ethics Committee. Vein donors gave written informed
consent. Table 2 summarizes methods used in this study.
Tissue decellularisation
Valve-bearing segments of the great saphenous vein with
a minimum length of 7 cm were obtained from patientsTable 2 Summary of experiments. TE, tissue engineered; SD, so
VG, Elastica van Gieson; IH, immunohistochemistry; MB, molecula
great saphenous vein (GSV) segments served as controls
Item Source Experim
Decellularisation GSV, human 90 min
Characterisation of 2D cultured
EC before re-seeding
GSV, human Two dif
FCS sup
hABS su
Characterisation of TE grafts
after re-seeding
SD/DNase-treated
GSV, EC
Five dif
protoco
FCS (gro
hABS (gundergoing cardiovascular bypass surgery. When found
competent by the manual strip test they were stored in
EGM-2 (Lonza, Switzerland). Vessels were washed in PBSA
(PAA, Austria, supplemented with penicillin/streptomycin
and Partricin, Biochrome, Germany) several times with
subsequent incubation in 20 mL of 4% sodium deoxycholate
solution under continuous shaking at 20 C for 90 min
(evaluation of decellularisation, nZ 8; re-seeding experi-
ments AeE, nZ 28). This was followed by three washing
steps and incubation with PBSA for 24 h each cycle. After-
wards the veins were stored in 30 mL PBSA. Veins that were
incubated for 90 min with sodium deoxycholate underwent
additional incubation with DNase reaction buffer (50 mM
TriseHCl, pH 7.5; 10 mM MgCl2) and 17 U/mL DNase I (Sig-
maeAldrich, Germany) for 120 min followed by two incu-
bations with reaction buffer alone for 15 min to remove
endonuclease. Decellularised veins were washed again
several times and then stored in PBS at 4 C.dium deoxycholate; DNase, DNase I; HE, haematoxylineeosin;
r biology/DNA content; EM, electron microscopy; fresh native
ental groups n Methods
SDþ 120 min DNase 8 HE, VG, MB
ferent culture media Total 28 IH (vWF, CD 31, FLK-1,
VE-Cadherin); MB (PCR)plemented medium 20
pplemented medium 8
ferent perfusion
ls
Total 28 HE, VG, IH (vWF, CD 31,
FLK-1, VE-Cadherin);
MB (PCR); EMups AeD) 20
roup E) 8
Table 3 Overview over re-seeding schedule; distinct
parameters are shown in Table 4
First EC seeding period (cell number 1.2 x 106)
24 h incubation in a roller apparatus at 0.1 rpm
24 h perfusion (parameters see Table 4)
Second EC seeding period (cell number 1.2 x 106)
24 h incubation in a roller apparatus at 0.1 rpm
24 h perfusion (parameters see Table 4)
Third EC seeding period (cell number 1.2 x 106)
24 h incubation in a roller apparatus at 0.1 rpm
72 h perfusion (parameters see Table 4)
End of re-seeding experiment
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Human venous ECs were enzymatically harvested from
great saphenous vein segments using 0.15% collagenase A
(Roche). ECs were expanded up to the 3rd passage using
FCS (nZ 20) or human AB serum (hABS; nZ 8) supple-
mented media (EGM-2).
Determining cell number in 2D culture
(24-well plates)
To determine the optimal cell number and medium
composition for re-seeding, decellularised vein segments
were cut longitudinally and tissue pieces with a surface of
1.5 cm2 obtained with a customised punch placed into one
hollow of a 24-well plate with their luminal surface on top.
Following detachment EC number was adjusted to 5 103,
1 104, 5 104 und 1 105. Cells were suspended in 1 mL
EGM-2 (supplemented with FCS or hABS), placed on top of
the veins and cultured for 3, 5, 7, 11 and 14 days (each
nZ 2). HE stainings were performed from frozen sections
for assessing adhesion and confluency.
Re-seeding in the bioreactor perfusion system
The decellularised veins were placed into a bioreactor (5%
CO2/95% air/37
C), facilitating longitudinal rotation of the
perfusion chamber as well as separate external and luminal
medium perfusion. In the previous ovine study a single
injection of 1.2 106 ECs at day 10 and repeated re-seeding
with smooth muscle cells was performed at every third day
using a constant flow of 7 mL/min.4 In the present study EC
re-seeding was achieved by a total of three consecutive
cycles beginning with an injection of 1.2 106 cultivated
cells into the lumen of a vein (6 cm length), followed by
24 h of rotating the bioreactor at 0.1 rpm for sedimentation
of the cells and 24 h of EGM-2 medium perfusion (third
circle 72 h), whereas flow direction and velocity were
modified between groups AeE. In brief, 3D re-seeding of 28
decellularised GSV was performed with antegrade perfusion
(A; nZ 8), bidirectional perfusion (B; nZ 8), bidirectional
perfusion/reduced flow (C; nZ 2), static conditions (D;
nZ 2) using FCS, or bidirectional perfusion/reduced flow
using 7.5% hABS (E; nZ 8) instead of FCS. Antegrade
perfusion implies a flow rate of 8 mL/min, reduced flow
means 4 mL/min, bidirectional perfusion is characterised
by repetitive circles of (1) 35 s antegrade perfusion, (2) 40 s
absence and (3) 10 s retrograde perfusion. The parameters
for sedimentation, flow velocity and direction are shown in
Tables 3 and 4.
Characterisation of matrix, cell cultures
and tissue-engineered neo-veins
Decellularised GSV, scaled-up EC and 3D-seeded tissue-
engineered valve containing neo-veins underwent immu-
nohistochemical and biomolecular characterisation by
reverse transcriptase PCR.
Matrix characterisation. The absence of cells was
proven by H&E and Elasticavan Gieson staining of cry-
osections as well as toluidine blue staining of semi-thinsections and agarose gel electrophoresis of purified
genomic DNA using DNeasy tissue kit (Qiagen, Germany)
according to manufacturer’s instructions. Native human
vein tissue served as controls for both analyses.
For an immunohistochemical staining (avidinebiotin
peroxidase technique) a small amount of EC was cultured
simultaneously on chamber slides (BectoneDickinson). The
following antibodies were used: CD 31 (Dako), VE-Cadherin
(Santa Cruz), FLK-1 (Santa Cruz), and von Willebrand factor
(vWF, Dako). Biotinylated horse-anti-mouse antibody
(Vector) served as secondary antibody. Negative controls
consisted of mouse IgG (Dako). Controls took place on
frozen sections of human native veins and tumour tissue
(FLK-1).
For reverse transcriptase-polymerase chain reaction
(PCR), total RNA was isolated using Tri-Reagent (Sigmae
Aldrich) according to manufacturer’s instruction. RNA
concentration was determined on SmartSpec spectropho-
tometer (Bio-Rad Laboratories). Using Superscript II reverse
transcriptase (Invitrogen) for 50 min at 42 C cDNA was
synthesized from 1.5 mg samples of total RNA. PCR was
performed using an initial 45 s hold at 94 C followed by 35
Table 4 Study groups and re-seeding conditions; proximal to distal directionZ antegrade; distal to proximal direc-
tionZ retrograde; bidirectionalZ see B
Study group n Re-seeding condition
A Re-seeding with constant
antegrade perfusion
8 8 mL/min (antegrade)
B Re-seeding with bidirectional
perfusion
8 (1) 35 s with 8 mL/min
(antegrade)
(2) 40 s no perfusion
(3) 10 s with 8 mL/min (retro-
grade, then continue at (1)
C Re-seeding with bidirectional
perfusion and reduced flow
2 Same as B2, except for flow
reduction from 8 mL/min to
4 mL/min
D Re-seeding without reperfusion 2 No perfusion
Each EC re-seeding period was fol-
lowed by incubation on the roller
apparatus with 0.1 rpm for 24 h
E Re-seeding with bidirectional
perfusion, reduced flow and
modified medium composition
8 Same as B3, except for medium
supplementation with hABS
instead of FCS
96 O.E. Teebken et al.cycles (1 min denaturizing at 94 C, 1 min annealing at
55 C, 3 min elongation at 72 C) with following EC primers:
b-actin (house keeping), CD 31, VE-Cadherin, FLK-1 and
vWF. For primer sequences see Table 5.
Statistics
All data are reported as meanG SD. The unpaired Student’s
t test was used for analyses. Statistical significance was
defined as p< 0.05. The SPSS statistical software package
11.0 for Windows was used.
Results
Decellularisation
Incubation of vein segments with 4% sodium deoxycholate
for 90 min and DNase I for 120 min led to completeTable 5 Primer used for EC characterisation, purchased
from MWG-Biotech, Germany
Target Sequence 50e30 cDNA-product
b-Actin gacctgactgactacctc 464/464/480
agtacttgcgctcaggag
CD 31 aggtgatagccccggtgg 412/409/412
ctgcttggccttggctttc
aactctttcacaatcaacagtgttg 580/?/580
ttggtagattctgaggtctgcatat
FLK-1 ggagcctacaagtgcttc 220/220/221
ggaacaaatctcttttctgg
aacaatcagagtggctctgaggaa 338/338/338
aattctgttaccatcaggaacaaac
VE-Cadherin gagaaagaactggacagag 329/?/332
cttgactgtgatgttggc
vWF cctgcctctgatgagatc 499/?/499
gcaaagcccaaggcatccacellularity of the vein valve and the vessel wall (nZ 8).
The matrix, particularly cross-linking and elastic fibres, was
preserved (Fig. 1). Gel electrophoresis confirmed the
absence of DNA fragments (Fig. 2).
Expansion and immunohistochemistry
of endothelial cells
After a culture period of three weeks cells of the 3rd
passage presented with the typical fusiform morphology,
width 30e40 mm and length 60e90 mm. The percentage of
ECs cultured with FCS (hABS) that were positive for FLK-1
was 91.55 7.80% (94.88 6.38%), VE-Cadherin
96.80 4.30% (97.88 2.95%), vWF 90.10 5.50%
(95.36 4.72%) and for CD 31 94.75 6.96% (97.13 4.67%)
(Fig. 3). Expression of vWF was significantly higher if hABS
was used instead of FCS (pZ 0.025) whereas no differences
were shown for CD 31 (pZ 0.385), FLK-1 (pZ 0.296) and
VE-Cadherin (pZ 0.524). EC marker expression in cultured
cells was not altered compared to native veins (positive
control) for FCS and hABS supplemented medium suggesting
absence of de-differentiation (Fig. 4).
Molecular biology of scaled-up endothelial cells
Exemplary analysis of PCR products using agarose gel
electrophoresis of EC cultivated with ECM-2 supplemented
with hABS as well as those supplemented with FCS showed
the expected bands for b-actin (positive control) and the
EC-specific primers for CD 31, FLK-1, VE-Cadherin and vWF
(Fig. 2B, Table 2).
Optimal cell number in 2D static culture
None of the veins cultured with FCS showed cells on the
luminal surface or the vessel wall regardless of the chosen
cell number and the duration of static cell culture. Only
Figure 1 (A) Frozen sections of decellularised great saphenous vein segments after 90 min incubation with 4% sodium deoxy-
cholate and subsequent incubation with DNase I for 120 min. Cross-linking of elastic (blue violet) and collagen fibres (pink) is
maintained similar to the native vein. (B) Fibres are not swollen and the valve sinus remains intact without adhesions. (C) Vein
segment re-seeded with constant flow (group A; 8 mL/min). The absence of blue-stained cell nuclei indicates that the luminal
surface as well as the matrix are completely acellular. (D) After bidirectional perfusion (group B) no cells are found in the vessel
wall and the surface but cell conglomerates in the lumen. (E) Cell conglomerates are found in the region of the valve as well (group
B). (F) Re-seeding utilizing reduced flow and hABS (group E) led to a confluent EC monolayer with blue cell nuclei on the vessel wall.
(G) EC can be shown on both sides of the valve. The leaflet is rolled in due to the freezing process (group E). (H) In Elastica van
Gieson stainings elastic and collagenous fibres appear to be well cross-linked and not swollen (group E). Vein wall (W), vessel lumen
(L), valve leaflet (V), cell conglomerate (Z). Bars in A, EZ 200 mm; in B, C, F, HZ 100 mm; in DZ 500 mm; in GZ 50 mm. Elastica
van GiesonZ A, B, H; HEZ CeG.
Venous Tissue Engineering 97when hABS supplemented medium and cell numbers as high
as were as 1 105, single EC was found after day 3 and
confluent layers were found after day 5 and thereafter. For
determination of the cell number needed for re-seeding,
representative decellularised vein segments of 7 cm length
were cut longitudinally. A width of approx. 25 mm was
obtained resulting in an area of 17.5 cm2 and in conse-
quence a required cell number of NZ 17.5 cm2 1 105/
1.5 cm2Z 1.166 106z 1.2 106.3D re-seeded valve containing segments
Macroscopy
Sufficient vein valve function was demonstrated in every
re-seeded segment using PBS perfusion. Following longitu-
dinal dissection, valve leaflets were movable like native
ones when rinsing with PBS or treating with closed forceps.
The luminal surface was smooth, glossy and white.
Figure 2 (A) Genomic DNA agarose gel electrophoresis of decellularised and DNase-treated (2e9; 120 min DNase I digestion) and
native (10e12) vein segments. Standard TriDye 1 kb DNA ladder (1, 13). (B) Agarose gel electrophoresis of PCR products of cultured
EC. CD 31 (3), FLK-1 (4), VE-Cadherin (5), and vWF (6). Positive controls for b-actin (positive control, 2); standard TriDye 100 bp DNA
ladder (1, 7). (C) Agarose gel electrophoresis electrophoresis of total RNA of re-seeded vein segments (2e8), standard; 0.24e9.5 kb
RNA ladder (1). (D) Agarose gel electrophoresis of PCR products of re-seeded vein segments; standard TriDye 100 bp DNA ladder (1,
2), b-actin (positive control, 2), CD 31 (3), FLK-1 (4), VE-Cadherin (5), vWF (6); negative controls for b-actin (7), CD 31 (8), FLK-1
(9), VE-Cadherin (10), vWF (11), respectively.
98 O.E. Teebken et al.Re-seeded veins were macroscopically indistinguishable
from native veins. These results were obtained indepen-
dent of the medium and supplement (Table 4).
Histology
All matrices (AeE) were comparable with those of
unseeded, decellularised veins (Table 4, Fig. 1). In group A
lumen and vessel wall were completely cell free. In groups
B and C (reduced flow) single cells were visible in theFigure 3 Immunohistochemical characterisation of cells
cultivated with FCS or hABS on chamber slides; proportion of
positive cells for FLK-1, VE-Cadherin, vWF, and CD 31. Mean -
 standard deviation.region of the valve sinus and the vessel lumen but no
adherence was apparent (Fig. 1). Static re-seeding in
group D did not result in improved cell adherence as well
and cell conglomerates were found in the vessel lumen
(Fig. 1D and E). Following bidirectional perfusion with
reduced flow and hABS medium supplementation (group E,
Fig. 1F) a confluent monolayer was found in 7 of 8 vein
segments.
Immunohistochemistry
In group A cells were absent (see histology). In groups BeD
cells and cell conglomerates were positive for vWF, VE-
Cadherin, CD 31 and FLK-1 and were therefore classified as
ECs. The cells forming the monolayer in 7/8 vessels in group
E were positive for vWF, VE-Cadherin, CD 31 and FLK-1 as
well (Fig. 3).
Molecular biology
Vein segments of group E were characterised by means of
molecular biology methods. The quality of total RNA was
proven by agarose gel electrophoresis. Specimen showed
distinct bands for 28S rRNA and for 18S rRNA for 7 of 8
re-seeded vein segments (Fig. 2C). For re-seeded vein
segment no. 3, the onewithout adhered cells in the histology,
no total RNA could be detected by spectrophotometry and by
agarose gel electrophoresis. After RT-PCR of the 7 samples of
group E in gel electrophoresis distinct bands were demon-
strated for all EC-specific primers (CD 31, FLK-1, VE-Cadherin
and vWF; Fig. 2D; for primers see Table 5).
Figure 4 (AeD) Immunohistochemical characterisation of EC cultivated with hABS supplemented medium on chamber slides. Cells
stained positive for the antibody are brown, negative cells are blue. Cells are positive for FLK-1 (A), CD 31 (B), vWF (C) demonstrating
endothelial cell characteristics and exhibit VE-Cadherin (C) demonstrating intercellular communication. (EeH) Native saphenous
vein tissue (positive controls); endothelial cells positive for FLK-1 (E), CD 31 (F), vWF (G) and VE-Cadherin (H) are shown on the
luminal surface. The wall contains myofibroblasts with blue nuclei. (IeL) Tissue-engineered neo-veins (group E). Cells positive for
FLK-1 (I), CD 31 (J), vWF (H), VE-Cadherin (L) show a distribution similar to a native vein. No cell nuclei are present in the vessel wall.
FLK-1 (A, E, I), CD 31 (B, F, J), vWF (C, G, H), VE-Cadherin (D, H, L). Bars in AeEZ 50 mm; in FeH, JeLZ 100 mm; in IZ 200 mm.
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Apart from superficial venous insufficiency valve reflux in the
deep venous system is an important cause for the develop-
ment of clinical symptoms. The transplantation of vein
valves from arm veins to the femoral or popliteal region has
been shown to improve symptoms such as pain and ulcer
healing.8 A variety of techniques utilizing valve repair,
transposition, homograft implantation or small intestinal
submucosa grafts were reported with encouraging results
(Tables 1a and 1b) but the artificial creation of implantable
complex structures like vein valves has not been successfully
tested in the long term yet.4,5,7 Synthetic, alloplastic
substitutes such as Dacron or polytetrafluoroethylene bear
the risk of thrombosis despite life-long anticoagulation in the
venous circulation.9 Autologous pericardium is not available
in satisfactory quantity for creating a long tube and addi-
tionally requires opening of another body cavity.10 Experi-
ence with xenogeneic (bovine or equine) pericardium or
decellularised venous homograft is very limited.10 Polymer-
based tubes were implanted in the venous/pulmonary
circulation with reasonable success.11,12
In order to develop a human vein valve and venous
conduit for the treatment of chronic venous insufficiency
decellularisation and re-seeding in a bioreactor system of
human vein segments were performed. Therefore, in this
study human valve containing saphenous veins that
provided the needed form and function served as a matrix
source. As a side effect of the use of biologic tissue, no
potential toxic or carcinogenic degradation products as
known after implantation of artificial polymers are found.13
Unexpectedly, we found that the methods previously
tested in the ovine study for decellularisation and re-seeding
of the vein segments had to be substantially modified for the
use in humans. Extended incubation times for sodium
deoxycholate and the DNase step were added. The histology
results of this study show that decellularisation with sodium
deoxycholate/DNase is complete and allows the adequate
preservation of the extracellular matrix including collagens
and elastins. Agarose gel electrophoresis revealed no
residual DNA, components with a potential immunologic
activity, in the matrix following decellularisation. On the
other hand, the presence of EC adhesion ligands such as
collagen IV and laminin among others is important for
successful and durable endothelial monolayer formation.
Schaner et al. used sodium dodecyl sulfate for decellular-
isation of human veins and hypothesised that the constructs
may be used as arterial bypass grafts.14 However that matrix
was potentially immunogenic, since it was after all not cell
free. Six percent of cells were allowed to remain in the
matrix in order to preserve the matrix structures.
The present study demonstrates the successful re-
endothelialisation of decellularised human vein segments
and vein valves with EC under simulated in vivo physiolog-
ical conditions that enabled significantly the formation of
EC monolayers. This re-endothelialisation is a prerequisite
for subsequent successful clinical application. In previous
studies our group has shown in an ovine model that EC
coverage is a crucial factor for patency and valve function
due to a significant reduction in thrombogenicity of the
decellularised matrix alone.4 This is related to the ability ofEC to produce and secrete mediators, e.g. prostacyclin,
proteins or tissue plasmin activator (TPA) that regulate
communication between matrix components.
Interestingly, we found that reduced flow and particu-
larly hABS are essential factors for the creation and pres-
ervation of a durable EC monolayer following cell seeding
and perfusion in a bioreactor (group E). The different
perfusion protocols investigated in groups AeD as well as
the use of FCS did not allow EC adhesion on the decellu-
larised matrix. In groups BeD cell conglomerates were
found, that contained EC positive for CD 31 and VE-Cad-
herin. It can be concluded that specific integrins were
upregulated by the flow parameters so that cell-to-cell
contacts were facilitated but the cell-to-matrix contacts,
which are needed for the adherence and monolayer
formation of human EC on the luminal vessel wall,
required distinct factors that in consequence are con-
tained in hABS but not FCS. The exact mechanisms cannot
be derived from our experiments. FCS and hABS are known
to contain a variety of factors in different concentrations
depending on origin, manufacturer or charge number.
A modulation of the expression of CD 31, FLK-1, VE-Cad-
herin, and vWF following exposure to different modes of
shear stress such as bidirectional/pulsatile flow was found
by others as well.15,16 Shear stress modulates gene
expression and in consequence cytoskeleton and cell
properties such as their capacity to adhere on or penetrate
surfaces.17 Vascular bed origin dictates flow pattern
regulation of endothelial adhesion molecules.18 Our suc-
ceeding experiments suggest that RNA of EC was not
degraded as shown in the agarose gel electrophoresis (18S
rRNA, 28S rRNA) and that ECs produce RNA for the cell-
specific markers such as vWF, CD 31, FLK-1 and VE-Cad-
herin (Fig. 2C and D). A single decellularised vein segment
(no. 3) was not successfully seeded. One explanation may
be EC donor related factors, e.g. advanced age, hyper-
cholesterinaemia, or tobacco use that cannot be evaluated
retrospectively.
Within this study, a decellularisation protocol was
successfully applied to human venous tissue and valves as
proven by the absence of donor cells. Thematrixwas then re-
seeded with endothelial cells in a bioreactor. Both, cultured
cells as well as the seeded neo-veins were extensively
characterised and the EC origin of the cells forming the
monolayer on the vessel lumenand the valveswas confirmed.
These properties are of utmost importance for clinical
appliance of such tissue-engineered grafts. Furthermore
they represent prerequisites for commercial application and
for complying with current regulations for tissue processing
and ethics. Using these well-characterised autologous adult
cells avoids questions about de-differentiation that always
arise if precursor cells or even embryonic cells are chosen.
Tissue-engineered vein segments and valve containing
neo-veins may be a therapeutic option in selected cases with
stenosed or obstructed veins and vein reflux not curable with
conservative and interventional methods or standard pros-
thetic replacement. The development of durable trans-
plants to treat vein valve insufficiency and post-thrombotic
syndrome is an extending field of research. However,
compared with the high socio-economical burden of the two
diseases, it is not appropriately recognised at present.4,19,20
Venous Tissue Engineering 101Limitations
EC characterisation by uptake of 1,10-dioctadecyl-3,3,30,30-
tetramethyl-indocarbocyanine labelled acetylated low
density lipoprotein (Dil-Ac-LDL) was not performed in this
study. However, in another series Dil-Ac-LDL uptake of
cultured EC showed cell function via scavenge receptor
activity, which confirmed the results of molecular biology
and immunohistochemistry (data not published yet).
Despite RNA production for EC-specific markers is shown
for cultured EC (Fig. 2D), it is impossible to prove from the
data that every cell is capable to do so, since the investi-
gations do not allow a quantitative assessment. Real-time
PCR has not been performed.
This is an in vitro study and the results are promising
with regard to the development of a functioning implant. It
can provide an informative basis for future human implan-
tations but certainly cannot predict the outcome as shown
by previous studies.5
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